The model combines estimates of skeletal muscle with routinely collected clinical data and unstructured notes and predicts the individual likelihood of cachexia.

The RAS(ON) inhibitor shrunk tumors in around 60 percent of patients with KRAS G12D mutations, according to a study presented at AACR's annual meeting.

The UK-based company will evaluate BFB-101 in up to five children with hereditary spastic paraplegia type 47 in a Phase I/II trial.

In the study, patients with advanced solid tumors must be HLA-A*02:01 positive and harbor a p53 R175H mutation.

Through its Precision Care Companion, McKesson wants to help oncologists bring personalized medicine to their patients ...

Biotech firms are engineering smarter, safer gene delivery systems to enhance the safety and efficacy of genetic medicines.

Cancer patients invariably develop resistance to targeted drugs, so drugmakers develop strategies to combat it before ...

During a Q1 earnings call, Merck CEO Rob Davis discussed pipeline diversification plans and effects of tariffs on its ...

The New York-based public benefit corporation is advancing three drug candidates for the extremely rare condition.

NEW YORK – Mosaic Therapeutics on Thursday said it has licensed two clinical-stage oncology programs from Astex Pharmaceuticals, which also has taken an equity stake in the firm. Mosaic will gain the ...

This small branch played a big role in advancing evidence-based genetic testing, and its loss diminishes US leadership in ...